Wikipedia

Hans-Georg Rammensee

(Redirected from Hans Georg Rammensee)

Hans-Georg Rammensee (born 12 April 1953) is a German immunologist and cancer researcher. He has been Chair Professor and Head of the Department of Immunology at the University of Tübingen since 1996.[1] Rammensee has contributed essentially to the research fields of MHC biology and tumor immunology and to the development of cancer immunotherapies.

Hans-Georg Rammensee
Rammensee in 2019
Born (1953-04-12) 12 April 1953 (age 71)
CitizenshipGermany
Alma materUniversity of Tübingen
Occupationimmunologist
EmployerUniversity of Tübingen
Scientific career
Thesis Minor histocompatibility antigens  (1982)
Doctoral advisorJan Klein

Life

edit

Rammensee studied Biology at the University of Tübingen and worked as a PhD student at the Max Planck Institute for Biology in Tübingen. After gaining his doctorate in 1982 he initially worked as a post-doctoral research fellow at Scripps Research Institute, La Jolla, USA. In 1985 he moved as a scientific member to the Basel Institute for Immunology, Basel, Switzerland. Two years later Rammensee returned to Max Planck Institute for Biology as a group leader at the department of immunogenetics. 1993 he became head of department at the Tumor-Virus-Immunology Section of the German Cancer Research Center, Heidelberg, Germany. The same year he was appointed professor at the Faculty of Theoretical Medicine of Heidelberg University. He has been a Full Professor at the University of Tübingen and Chair of the Department of Immunology at the Institute for Cell Biology since 1996.[2]

Research

edit

Since the late 1970s, Rammensee has been focusing on immunology with the specific aim of using tumor immunology to fight against cancer. He has contributed to genetics and immune regulation as well as to the understanding of minor H antigens, T cells and the major histocompatibility complex (MHC). His group has systematically developed bioinformatics tools for this purpose. In recent years, Rammensee has combined basic research on MHC biology with translational research, thus bringing tumor immunology into clinical practice. Currently he is focusing on the development of individualized cancer immunotherapy.[1] In 2000 and 2010, Rammensee co-founded three research-based companies. Immatics is involved in the development of cancer immunotherapies,[3] CureVac develops therapies based on messenger RNA (mRNA);[4] synimmune on recombinant antibodies.[5]

Awards

edit

Publications

edit
 
Scholia has a profile for Hans-Georg Rammensee (Q1577018).
  • Schuster H, Peper JK, Bösmüller HC, Röhle K, Backert L, Bilich T, Ney B, Löffler MW, Kowalewski DJ, Trautwein N, Rabsteyn A, Engler T, Braun S, Haen SP, Walz JS, Schmid-Horch B, Brucker SY, Wallwiener D, Kohlbacher O, Fend F, Rammensee HG, Stevanović S, Staebler A, Wagner P. The immunopeptidomic landscape of ovarian carcinomas. Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951. doi: 10.1073/pnas.1707658114.[14]
  • Kowalewski DJ, Schuster H, Backert L, Berlin C, Kahn S, Kanz L, Salih HR, Rammensee HG, Stevanovic S, Stickel JS. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75. doi: 10.1073/pnas.1416389112. Epub 2014 Dec 29.[15] Erratum in: Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6258-60.[16] Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6254-6[17]
  • Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988[18]
  • Britten CM, Singh-Jasuja H, Flamion B, Hoos A, Huber C, Kallen KJ, Khleif SN, Kreiter S, Nielsen M, Rammensee HG, Sahin U, Hinz T, Kalinke U. The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol. 2013 Oct;31(10):880-2. doi: 10.1038/nbt.2708[19]
  • Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, Kurek R, Loeser W, Bichler KH, Wernet D, Stevanović S, Rammensee HG. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 2002 Oct 15;62(20):5818-27[20]
  • Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 2000 Jan;30(1):1–7[21]
  • Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanović S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999 Nov;50(3-4):213-9. Review[22]
  • Falk K, Rötzschke O, Stevanović S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 1991 May 23;351(6324):290-6.
  • Rötzschke O, Falk K, Deres K, Schild H, Norda M, Metzger J, Jung G, Rammensee HG. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature. 1990 Nov 15;348(6298):252-4[23]
  • Deres K, Schild H, Wiesmüller KH, Jung G, Rammensee HG. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature. 1989 Nov 30;342(6249):561-4[24]

See also

edit

References

edit
  1. ^ a b "Rammensee, Hans Georg – Medizinische Fakultät – Universität Tübingen". Uni-tuebingen.de. Retrieved 10 December 2017.
  2. ^ "Home". Immunology-tuebingen.de. Retrieved 10 December 2017.
  3. ^ "Company – Immatics". immatics.com. Retrieved 10 December 2017.
  4. ^ "curevac.de: Company". Curevac.com. Retrieved 10 December 2017.
  5. ^ "SYNIMMUNE GmbH: Welcome". Synimmune.de. Retrieved 10 December 2017.
  6. ^ "Professor Hans-Georg Rammensee — Deutsch". Jung-stiftung.de. Retrieved 10 December 2017.
  7. ^ "DKTK Tübingen: Hans-Georg Rammensee receives 2013 German Cancer Aid Award". Dkfz.de. Retrieved 10 December 2017.
  8. ^ Communications, Bayer AG. "Bayer AG – Stiftungen". Bayer-foundations.com. Archived from the original on 27 September 2018. Retrieved 10 December 2017.
  9. ^ "European Commission : CORDIS : Projects and Results : Mutation-driven immunoediting of human cancer?". cordis.europa.eu. Retrieved 10 December 2017.
  10. ^ "Goethe-Universität — Preisträger seit 1952". Uni-frankfurt.de. Retrieved 10 December 2017.
  11. ^ "Robert Koch Stiftung – Hans-Georg Rammensee". Robert-koch-stiftung.de. Retrieved 10 December 2017.
  12. ^ "Liste der Leibniz-Preisträger 1986 – 2017" (PDF). Dfg.de. Archived from the original (PDF) on 12 March 2017. Retrieved 10 December 2017.
  13. ^ "Liste der Heinz Maier-Leibnitz-Preisträger 1978 bis 2017" (PDF). Dfg.de. Retrieved 10 December 2017.
  14. ^ Schuster, Heiko; Peper, Janet K.; Bösmüller, Hans-Christian; Röhle, Kevin; Backert, Linus; Bilich, Tatjana; Ney, Britta; Löffler, Markus W.; Kowalewski, Daniel J.; Trautwein, Nico; Rabsteyn, Armin; Engler, Tobias; Braun, Sabine; Haen, Sebastian P.; Walz, Juliane S.; Schmid-Horch, Barbara; Brucker, Sara Y.; Wallwiener, Diethelm; Kohlbacher, Oliver; Fend, Falko; Rammensee, Hans-Georg; Stevanović, Stefan; Staebler, Annette; Wagner, Philipp (14 November 2017). "The immunopeptidomic landscape of ovarian carcinomas". Proceedings of the National Academy of Sciences of the United States of America. 114 (46): E9942–E9951. Bibcode:2017PNAS..114E9942S. doi:10.1073/pnas.1707658114. PMC 5699044. PMID 29093164.
  15. ^ Kowalewski, Daniel J.; Schuster, Heiko; Backert, Linus; Berlin, Claudia; Kahn, Stefan; Kanz, Lothar; Salih, Helmut R.; Rammensee, Hans-Georg; Stevanovic, Stefan; Stickel, Juliane Sarah (13 January 2015). "HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)". Proceedings of the National Academy of Sciences of the United States of America. 112 (2): E166–175. Bibcode:2015PNAS..112E.166K. doi:10.1073/pnas.1416389112. PMC 4299203. PMID 25548167.
  16. ^ "Correction to Supporting Information for Kowalewski et al., HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)". Proceedings of the National Academy of Sciences of the United States of America. 112 (45): E6258–6260. 10 November 2015. Bibcode:2015PNAS..112E6258.. doi:10.1073/pnas.1519136112. PMC 4653161. PMID 26527660.
  17. ^ "Correction for Kowalewski et al., HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)". Proceedings of the National Academy of Sciences of the United States of America. 112 (45): E6254–6256. 10 November 2015. Bibcode:2015PNAS..112E6254.. doi:10.1073/pnas.1519135112. PMC 4653212. PMID 26483495.
  18. ^ Gubin, Matthew M.; Zhang, Xiuli; Schuster, Heiko; Caron, Etienne; Ward, Jeffrey P.; Noguchi, Takuro; Ivanova, Yulia; Hundal, Jasreet; Arthur, Cora D.; Krebber, Willem-Jan; Mulder, Gwenn E.; Toebes, Mireille; Vesely, Matthew D.; Lam, Samuel S.K.; Korman, Alan J.; Allison, James P.; Freeman, Gordon J.; Sharpe, Arlene H.; Pearce, Erika L.; Schumacher, Ton N.; Aebersold, Ruedi; Rammensee, Hans-Georg; Melief, Cornelis J. M.; Mardis, Elaine R.; Gillanders, William E.; Artyomov, Maxim N.; Schreiber, Robert D. (27 November 2014). "Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens". Nature. 515 (7528): 577–581. Bibcode:2014Natur.515..577G. doi:10.1038/nature13988. PMC 4279952. PMID 25428507.
  19. ^ Britten, Cedrik M; Singh-Jasuja, Harpreet; Flamion, Bruno; Hoos, Axel; Huber, Christoph; Kallen, Karl-Josef; Khleif, Samir N; Kreiter, Sebastian; Nielsen, Michaela; Rammensee, Hans-Georg; Sahin, Ugur; Hinz, Thomas; Kalinke, Ulrich (8 October 2013). "The regulatory landscape for actively personalized cancer immunotherapies". Nature Biotechnology. 31 (10): 880–882. doi:10.1038/nbt.2708. PMID 24104749. S2CID 19069323.
  20. ^ Weinschenk, Toni; Gouttefangeas, Cécile; Schirle, Markus; Obermayr, Florian; Walter, Steffen; Schoor, Oliver; Kurek, Raffael; Loeser, Wolfgang; Bichler, Karl-Horst; Wernet, Dorothee; Stevanović, Stefan; Rammensee, Hans-Georg (15 October 2002). "Integrated functional genomics approach for the design of patient-individual antitumor vaccines". Cancer Research. 62 (20): 5818–5827. PMID 12384544.
  21. ^ Hoerr, I.; Obst, R.; Rammensee, H. G.; Jung, G. (1 January 2000). "In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies". European Journal of Immunology. 30 (1): 1–7. doi:10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#. PMID 10602021. S2CID 196606232.
  22. ^ Rammensee, H.; Bachmann, J.; Emmerich, N. P.; Bachor, O. A.; Stevanović, S. (1 November 1999). "SYFPEITHI: database for MHC ligands and peptide motifs". Immunogenetics. 50 (3–4): 213–219. doi:10.1007/s002510050595. PMID 10602881. S2CID 1407069.
  23. ^ Falk, K.; Rötzschke, O.; Stevanović, S.; Jung, G.; Rammensee, H. G. (23 May 1991). "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules". Nature. 351 (6324): 290–296. Bibcode:1991Natur.351..290F. doi:10.1038/351290a0. PMID 1709722. S2CID 4342714.
  24. ^ Deres, K.; Schild, H.; Wiesmüller, K. H.; Jung, G.; Rammensee, H. G. (30 November 1989). "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine". Nature. 342 (6249): 561–564. Bibcode:1989Natur.342..561D. doi:10.1038/342561a0. PMID 2586628. S2CID 4316816.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Hans-Georg_Rammensee&oldid=1233737053"